Trial Profile
Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma (SERCC Study) Impact of Adverse Events Management in Elderly mRCC Patients Treated With Sorafenib
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2016
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Acronyms SERCC
- 05 Oct 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 17 Mar 2012 New source identified and integrated (EudraCT2010-019726-14; European Clinical Trials Database)
- 30 Apr 2011 New trial record